Globus Medical, Inc. (GMED)
USD 81.78
(-1.97%)
USD 81.78
(-1.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 133.14 Million USD | -41.59% |
| 2022 | 227.95 Million USD | 32.57% |
| 2021 | 171.95 Million USD | 54.31% |
| 2020 | 111.43 Million USD | -35.21% |
| 2019 | 171.98 Million USD | 1.57% |
| 2018 | 169.32 Million USD | 4.62% |
| 2017 | 161.84 Million USD | 4.99% |
| 2016 | 154.14 Million USD | -10.5% |
| 2015 | 172.22 Million USD | 24.47% |
| 2014 | 138.36 Million USD | 36.09% |
| 2013 | 101.67 Million USD | -11.43% |
| 2012 | 114.79 Million USD | 17.9% |
| 2011 | 97.36 Million USD | 11.04% |
| 2010 | 87.68 Million USD | 7.06% |
| 2009 | 81.9 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 42.12 Million USD | 316.13% |
| 2024 Q3 | 48.09 Million USD | -24.99% |
| 2024 Q2 | 64.12 Million USD | 52.23% |
| 2023 Q4 | 10.12 Million USD | 2405.69% |
| 2023 FY | 133.14 Million USD | -41.59% |
| 2023 Q1 | 56.4 Million USD | 4.4% |
| 2023 Q2 | 66.21 Million USD | 17.39% |
| 2023 Q3 | 404 Thousand USD | -99.39% |
| 2022 Q2 | 67.77 Million USD | 45.93% |
| 2022 Q4 | 54.02 Million USD | -9.5% |
| 2022 Q3 | 59.7 Million USD | -11.91% |
| 2022 FY | 227.95 Million USD | 32.57% |
| 2022 Q1 | 46.44 Million USD | 155.19% |
| 2021 Q2 | 45.87 Million USD | -15.9% |
| 2021 Q4 | 18.2 Million USD | -65.87% |
| 2021 FY | 171.95 Million USD | 54.31% |
| 2021 Q1 | 54.54 Million USD | -6.81% |
| 2021 Q3 | 53.32 Million USD | 16.25% |
| 2020 Q1 | 28.44 Million USD | -43.08% |
| 2020 FY | 111.43 Million USD | -35.21% |
| 2020 Q4 | 58.53 Million USD | 17.04% |
| 2020 Q3 | 50.01 Million USD | 295.65% |
| 2020 Q2 | -25.56 Million USD | -189.86% |
| 2019 Q3 | 42.06 Million USD | -1.88% |
| 2019 FY | 171.98 Million USD | 1.57% |
| 2019 Q1 | 37.07 Million USD | -14.27% |
| 2019 Q2 | 42.86 Million USD | 15.62% |
| 2019 Q4 | 49.98 Million USD | 18.83% |
| 2018 FY | 169.32 Million USD | 4.62% |
| 2018 Q4 | 43.25 Million USD | 12.92% |
| 2018 Q2 | 42.13 Million USD | -7.66% |
| 2018 Q1 | 45.63 Million USD | -5.64% |
| 2018 Q3 | 38.3 Million USD | -9.11% |
| 2017 Q1 | 40.31 Million USD | 12.85% |
| 2017 Q2 | 37.37 Million USD | -7.3% |
| 2017 Q3 | 35.79 Million USD | -4.22% |
| 2017 FY | 161.84 Million USD | 4.99% |
| 2017 Q4 | 48.36 Million USD | 35.1% |
| 2016 Q1 | 42.85 Million USD | -23.48% |
| 2016 Q3 | 37.65 Million USD | -0.71% |
| 2016 Q2 | 37.91 Million USD | -11.51% |
| 2016 Q4 | 35.72 Million USD | -5.12% |
| 2016 FY | 154.14 Million USD | -10.5% |
| 2015 Q1 | 38.52 Million USD | -2.84% |
| 2015 Q2 | 37.03 Million USD | -3.87% |
| 2015 Q3 | 40.67 Million USD | 9.84% |
| 2015 Q4 | 55.99 Million USD | 37.67% |
| 2015 FY | 172.22 Million USD | 24.47% |
| 2014 Q2 | 31.55 Million USD | -2.14% |
| 2014 Q4 | 39.64 Million USD | 13.52% |
| 2014 Q3 | 34.92 Million USD | 10.68% |
| 2014 Q1 | 32.24 Million USD | 1.56% |
| 2014 FY | 138.36 Million USD | 36.09% |
| 2013 FY | 101.67 Million USD | -11.43% |
| 2013 Q3 | 29.5 Million USD | 163.61% |
| 2013 Q4 | 31.74 Million USD | 7.61% |
| 2013 Q1 | 29.23 Million USD | 0.42% |
| 2013 Q2 | 11.19 Million USD | -61.71% |
| 2012 Q1 | 28.05 Million USD | 18.33% |
| 2012 FY | 114.79 Million USD | 17.9% |
| 2012 Q4 | 29.11 Million USD | 7.58% |
| 2012 Q3 | 27.06 Million USD | -11.47% |
| 2012 Q2 | 30.56 Million USD | 8.94% |
| 2011 Q4 | 23.71 Million USD | -10.62% |
| 2011 Q2 | 23.8 Million USD | 2.13% |
| 2011 FY | 97.36 Million USD | 11.04% |
| 2011 Q1 | 23.31 Million USD | 0.0% |
| 2011 Q3 | 26.52 Million USD | 11.42% |
| 2010 FY | 87.68 Million USD | 7.06% |
| 2009 FY | 81.9 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Abbott Laboratories | 6.47 Billion USD | 97.945% |
| Allurion Technologies Inc. | -78.07 Million USD | 270.524% |
| Artivion, Inc. | 5.74 Million USD | -2218.739% |
| Avanos Medical, Inc. | 4.2 Million USD | -3070.048% |
| Butterfly Network, Inc. | -145.61 Million USD | 191.437% |
| Butterfly Network, Inc. | -145.61 Million USD | 191.437% |
| Bio-Rad Laboratories, Inc. | 383.79 Million USD | 65.309% |
| Boston Scientific Corporation | 2.34 Billion USD | 94.317% |
| Perspective Therapeutics, Inc. | -15.18 Million USD | 976.973% |
| CONMED Corporation | 130.78 Million USD | -1.801% |
| Edwards Lifesciences Corporation | 1.53 Billion USD | 91.321% |
| Paragon 28, Inc. | -37.3 Million USD | 456.863% |
| Glaukos Corporation | -128.7 Million USD | 203.451% |
| Inspire Medical Systems, Inc. | -40.27 Million USD | 430.615% |
| Integer Holdings Corporation | 167.33 Million USD | 20.431% |
| Medtronic plc | 5.14 Billion USD | 97.412% |
| Nevro Corp. | -99.3 Million USD | 234.07% |
| Owlet, Inc. | -28.63 Million USD | 565.011% |
| Penumbra, Inc. | 73.55 Million USD | -81.02% |
| Vicarious Surgical Inc. | -80.66 Million USD | 265.053% |
| Smith & Nephew plc | 425 Million USD | 68.672% |
| Sonendo, Inc. | -57.74 Million USD | 330.577% |
| STERIS plc | 836.11 Million USD | 84.076% |
| Stryker Corporation | 3.88 Billion USD | 96.576% |
| Vapotherm, Inc. | -39.08 Million USD | 440.691% |
| Zimmer Biomet Holdings, Inc. | 1.27 Billion USD | 89.58% |